JP Morgan Chase’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $56.1M | Buy |
684,042
+338,025
| +98% | +$24.4M | ﹤0.01% | 1389 |
|
|
2026
Q1 | $22.7M | Sell |
346,017
-10,024
| -3% | -$710K | ﹤0.01% | 1975 |
|
|
2025
Q4 | $27M | Sell |
356,041
-134,893
| -27% | -$9.8M | ﹤0.01% | 1820 |
|
|
2025
Q3 | $30.1M | Sell |
490,934
-110,626
| -18% | -$5.76M | ﹤0.01% | 1766 |
|
|
2025
Q2 | $29.4M | Sell |
601,560
-1,922
| -0.3% | -$91.2K | ﹤0.01% | 1670 |
|
|
2025
Q1 | $30.8M | Sell |
603,482
-45,787
| -7% | -$2.28M | ﹤0.01% | 1593 |
|
|
2024
Q4 | $29.3M | Buy |
649,269
+86,488
| +15% | +$3.7M | ﹤0.01% | 1686 |
|
|
2024
Q3 | $20.9M | Sell |
562,781
-118,152
| -17% | -$3.96M | ﹤0.01% | 1958 |
|
|
2024
Q2 | $20.8M | Buy |
680,933
+63,547
| +10% | +$2.06M | ﹤0.01% | 1850 |
|
|
2024
Q1 | $18M | Sell |
617,386
-81,666
| -12% | -$2.29M | ﹤0.01% | 1975 |
|
|
2023
Q4 | $19.3M | Sell |
699,052
-183,500
| -21% | -$4.2M | ﹤0.01% | 1895 |
|
|
2023
Q3 | $19.8M | Sell |
882,552
-40,903
| -4% | -$1.52M | ﹤0.01% | 1689 |
|
|
2023
Q2 | $37.6M | Buy |
923,455
+55,002
| +6% | +$2.69M | ﹤0.01% | 1252 |
|
|
2023
Q1 | $42.1M | Buy |
868,453
+6,683
| +0.8% | +$305K | 0.01% | 1184 |
|
|
2022
Q4 | $32.9M | Buy |
861,770
+43,051
| +5% | +$1.79M | ﹤0.01% | 1333 |
|
|
2022
Q3 | $41.1M | Sell |
818,719
-47,476
| -5% | -$2.33M | 0.01% | 1142 |
|
|
2022
Q2 | $34.7M | Buy |
866,195
+76,460
| +10% | +$2.68M | ﹤0.01% | 1241 |
|
|
2022
Q1 | $29.5M | Buy |
789,735
+158,330
| +25% | +$6.1M | ﹤0.01% | 1476 |
|
|
2021
Q4 | $25.1M | Buy |
631,405
+37,239
| +6% | +$1.43M | ﹤0.01% | 1621 |
|
|
2021
Q3 | $22.1M | Buy |
594,166
+74,125
| +14% | +$3.04M | ﹤0.01% | 1681 |
|
|
2021
Q2 | $22M | Buy |
520,041
+142,876
| +38% | +$6.12M | ﹤0.01% | 1762 |
|
|
2021
Q1 | $17.9M | Buy |
377,165
+141,637
| +60% | +$8.41M | ﹤0.01% | 1858 |
|
|
2020
Q4 | $14.4M | Buy |
235,528
+66,502
| +39% | +$3.92M | ﹤0.01% | 1901 |
|
|
2020
Q3 | $7.99M | Sell |
169,026
-9,123
| -5% | -$449K | ﹤0.01% | 2209 |
|
|
2020
Q2 | $9.04M | Buy |
178,149
+18,826
| +12% | +$925K | ﹤0.01% | 1976 |
|
|
2020
Q1 | $7.11M | Buy |
159,323
+45,943
| +41% | +$2.31M | ﹤0.01% | 2005 |
|
|
2019
Q4 | $5.45M | Buy |
113,380
+91,806
| +426% | +$3.9M | ﹤0.01% | 2603 |
|
|
2019
Q3 | $730K | Buy |
21,574
+2,408
| +13% | +$105K | ﹤0.01% | 4007 |
|
|
2019
Q2 | $827K | Buy |
19,166
+4,163
| +28% | +$164K | ﹤0.01% | 3972 |
|
|
2019
Q1 | $564K | Buy |
15,003
+1,253
| +9% | +$42.1K | ﹤0.01% | 4141 |
|
|
2018
Q4 | $472K | Buy |
13,750
+1,292
| +10% | +$46.5K | ﹤0.01% | 4153 |
|
|
2018
Q3 | $586K | Buy |
12,458
+1,534
| +14% | +$63.5K | ﹤0.01% | 4208 |
|
|
2018
Q2 | $368K | Buy |
10,924
+2,852
| +35% | +$88.9K | ﹤0.01% | 4302 |
|
|
2018
Q1 | $218K | Sell |
8,072
-579
| -7% | -$14.7K | ﹤0.01% | 4338 |
|
|
2017
Q4 | $144K | Buy |
+8,651
| New | +$146K | ﹤0.01% | 4535 |
|
|
2017
Q1 | – | Sell |
-620,075
| Closed | -$6.76M | – | 5187 |
|
|
2016
Q4 | $6.76M | Sell |
620,075
-11,887
| -2% | -$125K | ﹤0.01% | 2212 |
|
|
2016
Q3 | $8.85M | Buy |
631,962
+286,021
| +83% | +$2.33M | ﹤0.01% | 1870 |
|
|
2016
Q2 | $2.43M | Buy |
345,941
+152,402
| +79% | +$1.12M | ﹤0.01% | 2705 |
|
|
2016
Q1 | $1.25M | Sell |
193,539
-16,387
| -8% | -$284K | ﹤0.01% | 2963 |
|
|
2015
Q4 | $6.8M | Buy |
209,926
+46,566
| +29% | +$1.37M | ﹤0.01% | 2037 |
|
|
2015
Q3 | $4.36M | Buy |
163,360
+23,022
| +16% | +$985K | ﹤0.01% | 2309 |
|
|
2015
Q2 | $6.75M | Buy |
140,338
+46,963
| +50% | +$2.74M | ﹤0.01% | 2198 |
|
|
2015
Q1 | $5.68M | Buy |
93,375
+17,638
| +23% | +$1.08M | ﹤0.01% | 2257 |
|
|
2014
Q4 | $3.92M | Buy |
75,737
+7,873
| +12% | +$347K | ﹤0.01% | 2559 |
|
|
2014
Q3 | $2.99M | Buy |
+67,864
| New | +$2.12M | ﹤0.01% | 2668 |
|
Other funds holding PTCT
RI
JT
JP Morgan Chase's PTCT Position: Q2 2026 in Review
JP Morgan Chase increased its PTC Therapeutics (PTCT) stake by 98% in Q2 2026, buying an estimated $24.4M and bringing the position to 684,042 shares worth $56.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1389.
JP Morgan Chase first reported a position in PTCT in Q3 2014 and has held it in 45 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- JP Morgan Chase held 684,042 shares of PTC Therapeutics worth $56.1M as of Q2 2026.
- JP Morgan Chase bought 338,025 PTC Therapeutics shares in Q2 2026, an estimated $24.4M.
- PTC Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #1389 holding.
- JP Morgan Chase first reported a position in PTC Therapeutics in Q3 2014 and has held it in 45 quarters since.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.